S Vinayak

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Komal Jhaveri, L.D. Eli, Hans Wildiers et al. · Annals of Oncology · 2023 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17

Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab

Panagiotis A. Konstantinopoulos, Pamela N. Münster, A. Forero-Torez et al. · Gynecologic Oncology · 2018 · 20 citations

Medicine, Oncology, Pharmacology +14

Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

Panagiotis A. Konstantinopoulos, Jasgit C. Sachdev, Lee S. Schwartzberg et al. · Annals of Oncology · 2017 · 13 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond <i>BRCA</i>: (TOPACIO/Keynote-162)

S Vinayak, SM Tolaney, Lee S. Schwartzberg et al. · Cancer Research · 2019 · 13 citations

Medicine, Oncology, Pharmacology +17

Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)

ML Telli, KC Jensen, Victor Abkevich et al. · Cancer Research · 2012 · 11 citations

Life Sciences, Genetics, Oncology +15